PC
TEVA icon

Paulson & Co’s Teva Pharmaceuticals TEVA Stock Holding History

Paulson & Co’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-2,450,000
Closed -$43.1M – 59
2017
Q3 		$43.1M Sell
2,450,000
-4,294,000
-64% -$96.6M 0.77% 25
2017
Q2 		$224M Sell
6,744,000
-4,253,300
-39% -$132M 3.03% 12
2017
Q1 		$353M Sell
10,997,300
-4,928,500
-31% -$168M 4.68% 5
2016
Q4 		$577M Sell
15,925,800
-151,100
-0.9% -$6.03M 7.28% 4
2016
Q3 		$740M Sell
16,076,900
-696,900
-4% -$36.4M 8.02% 4
2016
Q2 		$843M Sell
16,773,800
-3,828,400
-19% -$204M 8.56% 4
2016
Q1 		$1.1B Buy
20,602,200
+192,900
+0.9% +$11.3M 8.15% 3
2015
Q4 		$1.34B Buy
20,409,300
+2,409,300
+13% +$149M 8.01% 4
2015
Q3 		$1.02B Buy
18,000,000
+15,969,500
+786% +$1.04B 5.28% 6
2015
Q2 		$120M Buy
+2,030,500
New +$125M 0.55% 31

Other funds holding TEVA

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
HCM
Highfields Capital Management Boston, Massachusetts $68.3M AUM 21.64% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
NC
Northern Cross Boston, Massachusetts $279M AUM 1.98% 1-Year Est. Return
ACM
Abrams Capital Management Boston, Massachusetts $4.64B AUM 1.52% 1-Year Est. Return
Berkshire Hathaway
Berkshire Hathaway Omaha, Nebraska $263B AUM 16.68% 1-Year Est. Return
BC
Brahman Capital New York $275M AUM 18.08% 1-Year Est. Return

Paulson & Co's TEVA Position: Q4 2017 in Review

Paulson & Co sold out of Teva Pharmaceuticals (TEVA) in Q4 2017, closing a stake of 2,450,000 shares — an estimated $43.1M sold.

Paulson & Co first reported a position in TEVA in Q2 2015 and held it in 10 quarters. The position peaked at $1.34B in Q4 2015. 507 funds tracked by Wall St. Rank hold TEVA as of Q4 2017.

  • Paulson & Co reported no remaining Teva Pharmaceuticals position as of Q4 2017 after selling out during the quarter.
  • Paulson & Co sold 2,450,000 Teva Pharmaceuticals shares in Q4 2017, an estimated $43.1M.
  • Paulson & Co first reported a position in Teva Pharmaceuticals in Q2 2015 and held it in 10 quarters.
  • Paulson & Co's Teva Pharmaceuticals position peaked at $1.34B in Q4 2015.
  • 507 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q4 2017.

Based on Paulson & Co's 13F filing for Q4 2017, filed 14 Feb 2018.